Antidepressant Response Associated With Pioglitazone: Support for an Overlapping Pathophysiology Between Major Depression and Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
TO THE EDITOR: Metabolic syndrome independently contributes to the development of depressive symptoms (1). Several lines of evidence suggest that depression may be mediated by the pathophysiology underlying metabolic syndrome, including hypothalamic-pituitary-adrenal axis dysregulation, insulin resistance, immunoinflammatory activation, and oxidative stress (2). The thiazolidinedione class of antidiabetic drugs, through their neuroprotective, neurotrophic, insulin sensitizing, and anti-inflammatory effects, may be capable of altering these disturbances, leading to improved mood and enhanced cognition (3). We report the case of a patient with treatment refractory major depressive disorder and co-occurring metabolic syndrome (as evidenced by hypertension, abdominal obesity, and impaired fasting glucose) who demonstrated a marked and sustained antidepressant response when pioglitazone was prescribed for depression augmentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depressive symptoms and metabolic syndrome: is inflammation the underlying link?
Capuron, L., Su, S., Miller, A. H., Bremner, J. D., Goldberg, J., Vogt, G. J., Maisano, C., Jones, L., Murrah, N. V., & Vaccarino, V. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.019 · Cited by 219
Cited by
Wójtowicz, S., Strosznajder, A. K., Jeżyna, M., & Strosznajder, J. B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-02993-5 · Cited by 327
Metabolic syndrome and major depression
Marazziti, D., Rutigliano, G., Baroni, S., Landi, P., & Dell'Osso, L. (2014) · CNS Spectrums · doi:10.1017/s1092852913000667 · Cited by 210
“The thiazolidinedione class of antidiabetic drugs, in particular pioglitazone, may be capable of improving mood when prescribed for depression augmentation.(107,108) Clinical research currently is testing the safety and efficacy of different ‘‘metabolic’’ strategies for the management of mood disorders, notably for ne…”
BackgroundSepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Kemp, D. E., Ismail-Beigi, F., Ganocy, S. J., Conroy, C., Gao, K., Obral, S., Fein, E., Findling, R. L., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.033 · Cited by 109
“A case report of an individual with treatment refractory depression suggests that pioglitazone may be useful in reducing depression severity and improving the insulin resistance associated with metabolic syndrome (Kemp et al., 2009).”
BackgroundSelf-citationMetabolic Syndrome and Bipolar Disorder: What Should Psychiatrists Know?
de Almeida, K. M., Moreira, C. L. R. L., & Lafer, B. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00240.x · Cited by 64
“There is a case report of antidepressant response with pioglitazone in a patient with resistant depression [89].”
BackgroundRole of metabolic dysfunction in treatment resistance of major depressive disorder
Toups, M. S., & Trivedi, M. H. (2011) · Neuropsychiatry · doi:10.2217/npy.11.49 · Cited by 9
Metadata
- Authors
- KEMP, D. E., ISMAIL-BEIGI, F., & CALABRESE, J. R.
- Venue
- American Journal of Psychiatry
- Published
- 2009-05
- Volume
- 166
- Issue
- 5
- Pages
- 619-619
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2152596342
- Cited by
- 46
- References
- 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.